65 Investor presentation First six months of 2025 Novo Nordisk has broad and affo people with obesity for Wegovy ® ~55 million people with obesity have Wegovy ® coverage in the US People with obesity (millions) 110.0 30.0 20.0 60.0 Prevalence Commercial ~55.0 ~15.0 ~40.0 Access Medicaid and other Less than 2 million Full-year patients on NN AOMs in 2024 Medicare Part D AOM: Anti-obesity medications; CMS: Center for Medicare and Medicaid Services; CV: Cardiovascular disease; DoD: Department of D Source: Novo Nordisk Annual Report 2024, Internal analysis as per Q1 2025
Download PDF file